Clinical Trials for Small Cell Lung Cancer

A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This clinical trial targets patients with locally advanced or metastatic non-small cell lung cancer with an ECOG Performance Status of 2, examining the safety and efficacy of combining pembrolizumab, an anti-PD-1 monoclonal antibody, with either Pemetrexed or Nab-paclitaxel chemotherapy.

ClinicalTrials.gov ID: NCT04297605

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with stage IV or recurrent NSCLC who have progressed after prior systemic therapy (including PD-1/PD-L1 inhibitors) and lack EGFR, ALK, or ROS1 mutations, to receive atezolizumab (PD-L1 inhibitor) plus pirfenidone, an antifibrotic agent with immunomodulatory properties. Suitable patients should have adequate organ function, ECOG 0-2, and no significant comorbidities or prior severe pneumonitis.

ClinicalTrials.gov ID: NCT04467723

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with untreated, advanced or metastatic adenocarcinoma NSCLC (EGFR/ALK/ROS1 wild-type, ECOG 0-1) to receive first-line durvalumab (anti-PD-L1 antibody) and platinum/pemetrexed chemotherapy with either restorative microbiota therapy (an oral capsule designed to modulate the gut microbiome and potentially enhance immunotherapy efficacy) or placebo. Prior systemic therapy in the advanced/metastatic setting is not permitted.

ClinicalTrials.gov ID: NCT04105270

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with stage III NSCLC who have oligoprogressive (≤3 lesions) or polyprogressive (>3 lesions) disease after prior chemoradiation and anti-PD-L1 therapy, treating them with local consolidative therapy (radiation and/or surgery) plus durvalumab (an anti-PD-L1 antibody), with polyprogressive patients also receiving platinum-based chemotherapy. Patients with EGFR or ALK alterations and standard targeted options are excluded.

ClinicalTrials.gov ID: NCT04892953

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with stage IV non-squamous NSCLC who have either a sensitizing EGFR exon 19 or 21 mutation (after progressing on TKI therapy) or never smokers with wild-type tumors and randomizes them to standard carboplatin, pemetrexed, and bevacizumab with or without atezolizumab, a PD-L1 immune checkpoint inhibitor. Maintenance therapy consists of pemetrexed and bevacizumab, with or without atezolizumab per treatment arm.

ClinicalTrials.gov ID: NCT03786692

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with untreated, unresectable or metastatic non-squamous NSCLC harboring a KRAS G12C mutation and PD-L1 TPS <50%, evaluating the combination of adagrasib (a KRAS G12C inhibitor) with pembrolizumab and platinum-based chemotherapy. Patients must be naïve to prior KRAS G12C inhibitors and selected prior systemic therapies; those with active brain metastases are excluded.

ClinicalTrials.gov ID: NCT05609578

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant CfDNA in Plasma After Initiation of Osimertinib

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Eligible patients are adults with metastatic non-small cell lung cancer harboring activating EGFR mutations who have persistent EGFR-mutant ctDNA in plasma after initial osimertinib treatment. The trial compares continuation of osimertinib (a third-generation irreversible EGFR TKI) alone versus osimertinib combined with carboplatin and pemetrexed chemotherapy.

ClinicalTrials.gov ID: NCT04410796

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This trial enrolls adults with advanced, EGFR-mutated non-squamous NSCLC—either after progression on prior EGFR TKI therapy or with persistent mutant ctDNA on front-line osimertinib—to receive a combination of osimertinib and carotuximab, a monoclonal antibody targeting endoglin (CD105) to inhibit tumor angiogenesis. Eligible patients may have stable or treated brain metastases and must have measurable disease and available tumor tissue or willingness to undergo biopsy.

ClinicalTrials.gov ID: NCT05401110

Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced lung cancer (small cell or non-small cell), particularly those over 70 and/or with significant comorbidities or ECOG 0-3, who may not tolerate standard full-dose chemotherapy. Patients receive established cytotoxic chemotherapy regimens (such as platinum doublets or single agents), modified with prespecified reduced dosing based on age and comorbid health conditions.

ClinicalTrials.gov ID: NCT05800587

Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable NSCLC and ECOG performance status 0-2 (excluding those with actionable mutations or significant comorbidities) to receive standard first-line chemoimmunotherapy regimens, including pembrolizumab (anti-PD-1 antibody) plus histology- and PD-L1–guided platinum-doublet chemotherapy, comparing efficacy and safety outcomes between PS 2 and PS 0-1 patients.

ClinicalTrials.gov ID: NCT04253964